Drug interactions with smoking and nicotine

Česká verzia

Authors: A. Nazmutdinova; A. Khryakova; M. Šustková
Authors place of work: Ústav farmakologie 3. LF UK, Praha ; Přednosta: MUDr. Jiří Slíva, Ph. D. ; Univerzita Karlova
Published in the journal: Prakt. Lék. 2023; 103(5): 240-248
Category: Of different specialties

Summary

According to epidemiological research from 2022, roughly a quarter of the population of the Czech Republic regularly smokes or uses other forms of nicotine products. The popularity of electronic cigarettes and nicotine pouches has increased significantly, especially among young people aged 15 and over. A number of substances in tobacco smoke and nicotine itself interact with some medicinal substances at the level of pharmacokinetics or pharmacodynamics, which can significantly affect the pharmacotherapy used. This review article alerts clinicians to the potential interactions of tobacco smoking with some commonly prescribed medications and offers practical advice on how to avoid the risks. The article deals not only with smoking tobacco, classic cigarettes, cigars or pipes, but also with the use of their smokeless alternatives (IQOS) and tobacco-free nicotine products (electronic cigarets, nicotine sachets) and their possible interactions with medicines.

Zdroje

Bundesinstitut für Risikobewertung. Health risk assessment of nicotine pouches: updated BfR opinion No. 023/2022 of 7 October 2022. BfR-Stellungnahmen 2022; 2022(23): 1–21.
Csémy L, Dvořáková Z, Fialová A, a kol. Národní výzkum užívání tabáku a alkoholu v České republice 2022 [NAUTA] [online]. Praha: Státní zdravotní ústav 2023. Dostupné z: https://szu.cz/wp-content/uploads/2023/05/NAUTA_2022.pdf. [cit. 2023-10-23].
Desai HD, Seabolt J, Jann MW. Smoking in patients receiving psychotropic medications. CNS Drugs 2001; 15(6): 469–494.
DrugBank. Nicotine: uses, interactions, mechanism of action [online]. Dostupné z: https://go.drugbank.com/drugs/DB00184. [cit. 2023-10-23].
Drugs.com. Nicotine drug interactions. Dostupné z: https://www. drugs.com/drug-interactions/nicotine-index.html [cit. 2023-10-23].
Flowers L. Nicotine replacement therapy. Am J Psychiatry Resid J. 2016; 11(6): 4–7.
Food and Drug administration. Requip® (Ropinirole) label [online]. Dostupné z: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020658s024s026s027s030s032lbl.pdf. [cit. 2023-10-23].
Food and Drug administration. Xanax® (Alprazolam) label. United States Pharmacopeia. Dostupné z: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018276s045lbl.pdf [cit. 2023-10-23].
Forest V, Mercier C, Pourchez J. Considerations on dosimetry for in vitro assessment of e-cigarette toxicity. Respir Res 2022; 23(1): 1–10.
Goriounova NA, Mansvelder HD. Shortand long-term consequences of nicotine exposure during adolescence for prefrontal cortex neuronal network function. Cold Spring Harb Perspect Med 2012; 2(12): a012120.
Hartinger JM, Králíková E, Provazníková Z, et al. Lékové interakce se složkami tabákového kouře [online]. Adiktologie v preventivní a léčebné praxi 2021; 4(3): 182–184. Dostupné z: https://www.aplp.cz/wp-content/uploads/2021/10/07hartinger. pdf [cit. 2023-10-25].
Hukkanen J, Jacob III P, Peng M, et al. Effect of nicotine on cytochrome P450 1A2 activity. Br J Clin Pharmacol 2011; 72(5): 836–838.
Hukkanen J, Jacob III P, Peng M, et al. Effects of nicotine on cytochrome P450 2A6 and 2E1 activities. Br J Clin Pharmacol 2010; 69(2): 152–159.
Indiana University, School of Medicine. Drug Interactions Flockhart Table™ [online]. Dostupné z: https://drug-interactions. medicine.iu.edu/MainTable.aspx [cit. 2023-10-25].
Jogiraju VK, Heimbach T, Toderika Y, Taft DR. Physiologically based pharmacokinetic modeling of altered tizanidine systemic exposure by CYP1A2 modulation: Impact of drug-drug interactions and cigarette consumption. Drug Metab Pharmacokinet 2021; 37: 100375.
Leone A. Does smoking act as a friend or enemy of blood pressure? Let release Pandora’s box. Cardiol Res Pract 2011; 2011(1): 264894.
Leong H, Bonk ME. Bendamustine (Treanda) for chronic lymphocytic leukemia: a brief overview. P T 2009; 34(2): 73–76.
Lucas C, Martin J. Smoking and drug interactions. Aust Prescr 2013; 36(3): 102–104.
Maideen NMP. Tobacco smoking and its drug interactions with comedications involving CYP and UGT enzymes and nicotine. World J Pharmacol 2019; 8(2): 14–25.
Ryan J, Patel J, Lucas CJ, Martin JH. Tobacco smoking and its potential drug interactions. Pharm J 2019; 11(1): 1–17.
Schaffer SD, Yoon S, Zadezensky I. A review of smoking cessation: Potentially risky effects on prescribed medications. J Clin Nurs 2009; 18(11): 1533–1540.
U.S. Department of Health and Human Services. How tobacco smoke causes disease: the biology and behavioral basis for smoking-attributable disease: a report of the surgeon general. Atlanta: U.S. Atlanta: Department of Health and Human Services 2010 [online]. Dostupné z: https://www.ncbi.nlm.nih.gov/books/ NBK53017/pdf/Bookshelf_NBK53017.pdf [cit. 2023-10-25].
Uguna CN, Snape CE. Should IQOS emissions be considered as smoke and harmful to health? A review of the chemical evidence. ACS Omega 2022; 7(26): 22111–22124.
zákon č. 59/2023 Sb., kterým se mění zákon č. 65/2017 Sb. o ochraně zdraví před škodlivými účinky návykových látek, ve znění pozdějších předpisů [online]. Dostupné z: www.zakonyprolidi.cz/cs/2023-59 [cit. 2023-10-25].
Zevin S, Benowitz NL. Drug interactions with tobacco smoking: an update. Clinical Pharmacokinetics 1999; 36(6): 425−438.